CASI Pharmaceuticals, Inc. (CASI) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CASI currently has 18.5M outstanding shares. with significant dilution risk as 15.3M authorized shares could dilute existing holders by 82.6%. The company has significantly diluted shareholders by 36.57% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
20-F filing | 18.5M shares outstanding |
19M | 15M |
| Mar 31, 2025 |
20-F filing | 15.3M shares outstanding |
15M | 19M |
| Dec 20, 2024 |
F-3 filing: This is an F-3 filing for a shelf offering of up to $200 million in various securities, including ordinary shares, preferred shares, and subscription rights, with the possibility of future offerings of ordinary shares up to $50 million. |
15M | 18M |
| Aug 16, 2024 |
F-3 filing: This is an F-3 filing for CASI Pharmaceuticals, Inc. regarding the offering of 3,000,000 ordinary shares, including shares issuable upon exercise of warrants, by selling shareholders. |
13M | 3M |
| May 03, 2024 |
F-3 filing: The company may offer and sell from time to time, in one or more offerings, up to an aggregate of $50.0 million of any combination of ordinary shares, debt securities, preferred shares, and subscription rights. |
13M | 0 |
| Mar 28, 2024 |
20-F filing | 13.4M shares outstanding |
13M | 0 |
| Apr 26, 2023 |
20-F filing | 13.6M shares outstanding |
14M | 0 |